mild cognitive impairment information from trusted sources:
Mild cognitive impairment
Mild cognitive impairment is a transition stage between the cognitive decline of normal aging and the more serious problems caused by Alzheimer's disease.
Cognex (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.Evidence of Cognex's effectiveness in the treatment of dementia of the Alzheimer's type derives from results of two adequate and well-controlled clinical investigations that compared tacrine and placebo on both a performance based measure of cognition and a clinician's global assessment of change. (See CLINICAL PHARMACOLOGY Section: Clinical Trial Data).
Cognex (tacrine hydrochloride) is a reversible cholinesterase inhibitor, known chemically as 1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate. Tacrine hydrochloride is commonly referred to in the clinical and pharmacological literature as THA. It has an empirical formula of C13H14N2&bull, HCl &bull, H2O and a molecular weight of 252.74. The molecular formula of tacrine hydrochloride is: Tacrine hydrochloride is a white solid and is freely soluble in distilled water, 0.1N hydrochloric acid, acetate buffer (pH 4.0), phosphate buffer (pH 7.0 to 7.4), methanol, dimethylsulfoxide (DMSO), ethanol, and propylene glycol. The compound is sparingly soluble in linoleic acid and PEG 400. Each capsule of Cognex contains tacrine as the hydrochloride. Inactive ingredients are hydrous lactose, magnesium stearate, and microcrystalline cellulose. The hard gelatin capsules contain gelatin, NF, silicon dioxide, NF, sodium lauryl sulfate, NF, and the following dyes: 10 mg: D&C Yellow #10, FD&C Green #3, titanium dioxide, 20 mg: D&C Yellow #10, FD&C Blue #1, titanium dioxide, 30 mg: D&C Yellow #10, FD&C Blue #1, FD&C Red #40, titanium dioxide, 40 mg: D&C Yellow #10, FD&C Blue #1, FD&C Red #40, D&C Red #28, titanium dioxide. Each 10-, 20-, 30-, and 40-mg Cognex capsule for oral administration contains 12.75, 25.50, 38.25, and 51.00 mg of tacrine HCl, respectively. Cognex (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Evidence of Cognex's effectiveness in the treatment of dementia of the Alzheimer's type derives from results of two adequate and well-controlled clinical investigations that compared tacrine and placebo on both a performance based measure of cognition and a clinician's global assessment of change. (See CLINICAL PHARMACOLOGY Section: Clinical Trial Data).
Vision Impairment and Blindness
Vision impairment, or low vision, means that even with eyeglasses, contact lenses, medicine or surgery, you don't see well. Vision impairment can range from mild to severe. The leading causes of vision impairment and blindness in the United States are age-related eye diseases: macular degeneration, cataract and glaucoma. Other eye disorders, eye injuries and birth defects can also cause vision loss. A loss of vision means that you may have to reorganize your life and learn new ways of doing things. If you have some vision, visual aids such as special glasses and large print books can make life easier. There are also devices to help those with no vision, like text-reading software and braille books.
Possible Early Dementia
Dementia is a serious brain disorder that interferes with a persons ability to carry out everyday tasks. The key feature of dementia is a decline in cognitive functions. These are mental processes such as thinking, reasoning, learning, problem solving, memory, language, and speech. Other features that occur frequently in dementia include changes in personality and behavior. Generally, these symptoms are not considered dementia unless they have continued unabated for at least 6 months. Dementia has many different causes. Some may be reversible, such as certain infections, drug intoxication, and liver diseases. Of the irreversible causes, the most common in older adults is Alzheimer disease. Although dementia is frequently linked to old age (getting senile), it is not a normal part of aging. Even children with certain degenerative brain disorders can develop dementia. Alzheimer disease usually begins with mild, slowly worsening memory loss. Many older people fear that they have Alzheimer disease because they cant find their eyeglasses or remember someones name.
Cognitive behavioural therapy (CBT) is the term for a number of therapies that are designed to help solve problems in people's lives, such as anxiety, depression, post-traumatic stress disorder (PTSD) or drug misuse.
Alzheimer's Association - Mild Cognitive Impairment
Nov 17, 2010 ... Mild cognitive impairment (MCI) a condition in which a person has problems with memory, language, or another mental function severe enough ...
Mild cognitive impairment - Wikipedia, the free encyclopedia
Mild cognitive impairment (MCI, also known as incipient dementia, or isolated memory impairment) is a diagnosis given to individuals who have cognitive ...
Mild Cognitive Impairment: eMedicine Neurology
Aug 11, 2010 ... Overview: Mild degrees of cognitive impairment, particularly when self-reported by patients, pose a substantial challenge to the clinician.
Mild Cognitive Impairment - Diagnosis and Treatment Options at ...
Mild Cognitive Impairment (MCI), also known as benign senescent forgetfulness, treatment options at Mayo Clinic.